(carboxymethyl(3-phenylpropyl)amino)acetic acid | 300804-20-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (carboxymethyl(3-phenylpropyl)amino)acetic acid
• 英文别名: 2-[Carboxymethyl(3-phenylpropyl)amino]acetic acid
• CAS: 300804-20-0
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: UYGNATLCLXEGCB-UHFFFAOYSA-N

物化性质

• 沸点：
  460.7±40.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (carboxymethyl(3-phenylpropyl)amino)acetic acid 在 三异丙基硅烷 、 乙酸酐 、 N,N-二异丙基乙胺 、 三氟乙酸 、 三氟乙酸酐 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (S)-N-(2-((1-(tert-butoxy)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-N-(3-phenylpropyl)glycine compound with formic acid (1:1)
  参考文献：
  名称：

  咪唑衍生的2- [ N-氨基甲酰基甲基-烷基氨基]乙酸与人胰岛素降解酶的双重结合剂的结构-活性关系

  摘要：

  胰岛素降解酶（IDE）是一种锌金属蛋白酶，可降解小的淀粉样肽，例如β-淀粉样蛋白和胰岛素。到目前为止，IDE特异性药理抑制剂的缺乏影响了对其在阿尔茨海默氏病生理病理学中的作用，淀粉样蛋白-α清除及其作为潜在治疗靶点的验证的了解。击中1以前是通过高通量筛选发现的。在这里，我们描述了结构活性研究，该研究需要合成48个类似物。我们发现，尽管羧酸，咪唑和叔胺对于活性至关重要，但甲酯已成功优化为酰胺或1,2,4-恶二唑。除了提高活性外，还优化了化合物在血浆和微粒体中的溶解度，亲脂性和稳定性。一些化合物在IDE的外位或催化位点上的对接或共结晶为IDE抑制提供了结构基础。在体内测定了最佳化合物44和46的药代动力学特性。结果是44（BDM43079）其甲酯前体48（BDM43124）是探索IDE作用的有用化学探针。

  DOI：

  10.1016/j.ejmech.2014.12.005
• 作为产物：
  描述：

  3-苯基-1-丙胺 、 氯乙酸 在 sodium hydroxide 、 盐酸 作用下， 以 水 、 乙醇 为溶剂， 以61%的产率得到(carboxymethyl(3-phenylpropyl)amino)acetic acid
  参考文献：
  名称：

  Nickel(II) complexes with N-aralkyliminodiacetic acids: Preparation, spectroscopic, structural and thermal characterization

  摘要：

  The reactions of N-aralkyl derivatives of iminodiacetic acid (H(2)Bnida, H(2)Peida, H(2)Ppida, o-H(2)Cbida, Bn = benzyl, Pe = 2-phenylethyl, Pp = 3-phenylprop-1-yl, o-Cb = o-chlorobenzyl) with nickel(II) chloride hexahydrate or nickel(II) acetate tetrahydrate in aqueous solutions were studied. Five new nickel(II) complexes [Ni(Bnida)(H2O)(3)]center dot H2O (1), [Ni(Peida)(H2O)(3)] (2), [Ni(Ppida)(H2O)(3)]center dot H2O (3a), [Ni(Ppida)(H2O)(3)] (3b) and [ Ni(o-Cbida)(H2O)(3)] (4) were prepared and characterized by infrared spectroscopy and thermal analysis (TGA-DTA). The crystal structures of 1 and 3b were determined by single-crystal X-ray structural analysis. The octahedral coordination environment around the nickel(II) ion in 1 and 3b consists of an O,N,O'-tridentate N-aralkyliminodiacetate ion and three water molecules arranged in a fac-position. The molecules in the crystal structures of 1 and 3b are connected into a complicated hydrogen-bonded 2D network, dominated by the O-H center dot center dot center dot O hydrogen bonds. These 2D networks are in turn assembled into a 3D architecture only by weak van der Waals interactions. (C) 2013 Elsevier B. V. All rights reserved.

  DOI：

  10.1016/j.ica.2013.02.017

文献信息

• Ligands of insulin degrading enzyme and their uses
  申请人：Université de Lille 2 Droit et Santé

  公开号：EP2371421A1

  公开（公告）日：2011-10-05

  The invention relates to ligands of insulin degrading enzyme and to their uses. The ligands of the invention are non peptidic and bind specifically to the exosite of insulin degrading enzyme. They are useful, in particular a use in the pharmaceutical field.

  该发明涉及胰岛素降解酶的配体及其用途。该发明的配体为非肽类，并特异性结合到胰岛素降解酶的外位点。它们在药物领域中特别有用。
• Preparation and characterization of palladium(II) complexes with N-arylalkyliminodiacetic acids. Catalytic activity of complexes in methoxycarbonylation of iodobenzene
  作者：Neven Smrečki、Boris-Marko Kukovec、Jarosław Jaźwiński、Ye Liu、Jing Zhang、Ana-Matea Mikecin、Zora Popović

  DOI：10.1016/j.jorganchem.2013.10.010

  日期：2014.6

  tetrachloropalladate(II) in aqueous solutions were investigated. Five new palladium(II) complexes [Pd(HBnida)2]·2H2O (1a), [Pd(HBnida)2] (1b), [Pd(HPeida)2] (2), [Pd(HPpida)2] (3) and [Pd(o-HCbida)2] (4) were prepared and characterized by infrared spectroscopy, 1H, 13C and 15N NMR spectroscopy and thermal analysis (TGA/DTA). The crystal structure of 1a was determined by single-crystal X-ray structural analysis. The

  的反应Ñ亚氨基二乙酸的芳基烷基衍生物（H 2 Bnida，H 2佩达，H 2 Ppida，ö -H 2 BN =苄基，PE = 2-苯基乙基; PP = 3-苯基丙-1-基; Cbida ö用四氯钯酸钠（II）在水溶液中研究了-Cb = 邻氯苄基）。五个新的钯（II）配合物[Pd（HBnida）2 ]·2H 2 O（1a），[Pd（HBnida）2 ]（1b），[Pd（HPeida）2 ]（2），[Pd（HPpida）2 ]（3）和[Pd（o-HCbida）2 ]（4）的制备并通过红外光谱，1 H，13 C和15 N NMR光谱和热分析（TGA / DTA）进行表征。的晶体结构1a中，通过单晶X射线结构分析确定。1a分子中的钯（II）离子与两个N，O-齿状N-苄基-氢亚氨基二乙酸根离子呈正方形平面配位。复合物1a是反式-异构体。在三种人类细胞系上测试了复合物的抗肿瘤特性。这些化合物没有明显抑制结肠（HCT
• Diene Polymerisation
  申请人：Jacobsen Grant Berent

  公开号：US20100022724A1

  公开（公告）日：2010-01-28

  A process for producing homopolymers or copolymers of conjugated dienes comprising contacting monomeric material comprising at least one conjugated diene with a catalyst system comprising two or more different transition metal compounds and optionally one or more activators. Preferred transition metal compounds are based on cobalt and chromium, especially complexes thereof having benzimidazole ligands.

  生产共轭二烯的同聚物或共聚物的过程，包括将至少含有一种共轭二烯的单体材料与催化剂体系接触，所述催化剂体系包括两种或更多不同的过渡金属化合物和可选的一个或多个活化剂。首选的过渡金属化合物基于钴和铬，特别是具有苯并咪唑配体的配合物。
• Diene polymerisation
  申请人：Ineos Europe Limited

  公开号：US08124698B2

  公开（公告）日：2012-02-28

  Process for producing homopolymers or copolymers of conjugated dienes by contacting monomeric material having at least one conjugated diene with a catalyst system including two or more different transition metal compounds and optionally one or more activators. Preferred transition metal compounds are based on cobalt and chromium, especially complexes thereof having benzimidazole ligands.

  通过将至少含有一种共轭二烯的单体材料与包含两种或更多不同过渡金属化合物和可选的一个或多个活化剂的催化剂体系接触，生产共轭二烯的同聚物或共聚物的过程。首选的过渡金属化合物基于钴和铬，特别是具有苯并咪唑配体的配合物。
• Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis
  作者：Julie Charton、Marion Gauriot、Qing Guo、Nathalie Hennuyer、Xavier Marechal、Julie Dumont、Malika Hamdane、Virginie Pottiez、Valerie Landry、Olivier Sperandio、Marion Flipo、Luc Buee、Bart Staels、Florence Leroux、Wei-Jen Tang、Benoit Deprez、Rebecca Deprez-Poulain

  DOI：10.1016/j.ejmech.2014.04.009

  日期：2014.5

  Insulin degrading enzyme (IDE) is a highly conserved zinc metalloprotease that is involved in the clearance of various physiologically peptides like amyloid-beta and insulin. This enzyme has been involved in the physiopathology of diabetes and Alzheimer's disease. We describe here a series of small molecules discovered by screening. Co-crystallization of the compounds with IDE revealed a binding both at the permanent exosite and at the discontinuous, conformational catalytic site. Preliminary structure activity relationships are described. Selective inhibition of amyloid-beta degradation over insulin hydrolysis was possible. Neuroblastoma cells treated with the optimized compound display a dose-dependent increase in amyloid-beta levels. (c) 2014 Elsevier Masson SAS. All rights reserved.